Quick Answer
Kyverna Therapeutics, Inc. reported Shares Outstanding of 60.39 million shares for fiscal year 2025.
Kyverna Therapeutics, Inc. Shares Outstanding — Annual History
| Fiscal Year | Shares Outstanding | YoY Change |
|---|---|---|
| 2025 | 60.39M | +39.7% |
| 2024 | 43.21M | +3356.9% |
| 2023 | 1.25M | — |
Quarterly Shares Outstanding
| Quarter Ending | Shares Outstanding | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | 43.79M | +1.5% | +1.3% |
| June 30, 2025 | 43.24M | +0.2% | +0.1% |
| March 31, 2025 | 43.22M | +0.2% | +0.0% |
| December 31, 2024 | 43.21M | +3356.9% | +0.1% |
| September 30, 2024 | 43.17M | — | +0.0% |
| June 30, 2024 | 43.15M | — | +0.1% |
| March 31, 2024 | 43.12M | — | +3348.9% |
| December 31, 2023 | 1.25M | — | — |
- Kyverna Therapeutics, Inc. showed an increase of +39.7% in Shares Outstanding compared to the prior fiscal year.
- Over the 2023–2025 period, Kyverna Therapeutics, Inc.’s shares outstanding has grown by 4730.8% (from 1.25 million shares to 60.39 million shares).
- The most recent figure is from Kyverna Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: